April 14, 2010 (FinancialWire) — QLT Inc. (NASDAQ: QLTI) (TSX: QLT) said Dipak Panigrahi, M.D., will join QLT as senior vice-president, research and development and chief medical officer. He will report to Bob Butchofsky, president and chief executive officer, effective in May 2010.

Dr. Panigrahi will be responsible for the QLT Research and Development portfolio, including clinical, pharmaceutical, and formulation development, as well as regulatory affairs. He was vice president, glaucoma development at Alcon Laboratories, Inc., where he was responsible for managing the development of the company's glaucoma franchise. Panigrahi received his B.A. in psychology from The Johns Hopkins University in Baltimore, MD and his masters degree and medical doctorate from The Medical College of Pennsylvania-Hahnemann School of Medicine in Philadelphia, PA. He completed his clinical training in ophthalmology at the Georgetown – Washington Hospital Center in Washington, DC.

QLT Inc. is a pharmaceutical company dedicated to the development and commercialization of innovative therapies for the eye.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[frlylrf] [biomedphrm] [clvloy]